The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Original Article: FDA Approves Rucaparib for Recurrent Ovarian Cancer Maintenance Therapy